News
Information, updates and press releases issued by Collaborations Pharmaceuticals.
Collaborations Pharmaceuticals, Inc. Announces Major Updates To 2022 Pipeline
Collaborations Pharmaceuticals, Inc. (CPI) announced major updates to their drug discovery research and development pipeline aided by machine learning software.
Collaborations Pharmaceuticals, Inc. Awarded An SBIR From NIH/NIDA To Develop Drugs For Opioid Abuse Treatment
Raleigh – The National Institute on Drug Abuse has awarded a $256,220 SBIR grant to Collaborations Pharmaceuticals, Inc.
Collaborations Pharmaceuticals, Inc. Awarded A Matching Grant From One North Carolina Small Business Program
Raleigh – The North Carolina Department of Commerce has awarded a matching award totaling $75,000 to Collaborations Pharmaceuticals, Inc. to support cutting edge science.
Stepan Company Has Licensed Collaborations Pharmaceuticals, Inc. MegaTox Machine Learning Software
Raleigh – Collaborations Pharmaceuticals, Inc. (CPI) announced today that they have entered into an agreement with Stepan Company to license CPI’s MegaTox® machine learning software for predicting toxicology properties to aid their decision making and regulatory processes.
Collaborations Pharmaceuticals, Inc. Announce A Phase I SBIR Award From NIEHS/NIH To Develop Machine Learning Software Approaches To Predict Acetylcholinesterase Inhibition
Raleigh – The National Institute of Environmental Health Sciences (NIEHS) has awarded $256,385 to Collaborations Pharmaceuticals, Inc. (CPI) to develop new machine learning models for prediction of acetylcholinesterase inhibition.
Collaborations Pharmaceuticals, Inc. Announce A Phase IIB SBIR Award From NIGMS/NIH To Develop Assay Central As A Machine Learning Software Suite
Raleigh – The National Institute of General Medical Sciences (NIGMS) has awarded $1,709,804 to Collaborations Pharmaceuticals, Inc. (CPI) to develop new capabilities in their Assay Central® machine learning software that will be applied to drug discovery research.
Three Common Antiviral Drugs Potentially Effective Against COVID-19
An international team of researchers has found that three commonly used antiviral and antimalarial drugs are effective in vitro at preventing replication of SARS-CoV-2, the virus that causes COVID-19.